Gilead’s Trodelvy extends breast cancer survival by 3.2 months -study
By Deena Beasley (Reuters) – Gilead Sciences Inc’s Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data…